ライフサイエンスコーパス: leukotriene C

1 tive inhibition by both amphiphiles, such as leukotriene C(4) (K(i(app)), 1.5 microM), glycolithochol

2 Leukotriene B(4) (LTB(4)) and leukotriene C(4) (LTC(4)) act through G protein-coupled

3 gical concentrations of the receptor agonist leukotriene C(4) (LTC(4)) evoke repetitive cytoplasmic C

4 ivate eosinophils and basophils for enhanced leukotriene C(4) (LTC(4)) generation by distinct signali

5 ptors on leukocytes to induce degranulation, leukotriene C(4) (LTC(4)) generation, and chemokine CCL2

6 e signaling cascades leading to secretion of leukotriene C(4) (LTC(4)) is controlled independently of

7 inophils to affect their capacity to release leukotriene C(4) (LTC(4)) or their preformed stores of c

8 Both fMLP-induced AA release and leukotriene C(4) (LTC(4)) secretion were inhibited conce

9 Leukotriene C(4) (LTC(4)) synthase conjugates LTA(4) wit

10 glutathione S-transferase and membrane-bound leukotriene C(4) (LTC(4)) synthase.

11 hese double-mutant mice are unable to cleave leukotriene C(4) (LTC(4)) to LTD(4), indicating that thi

12 ration from skin to lymph nodes utilizes the leukotriene C(4) (LTC(4)) transporter multidrug resistan

13 The uptake of 50nM [3H]leukotriene C(4) (LTC(4)) was measured in a 96-well micr

14 logically active glutathione adduct has been leukotriene C(4) (LTC(4)), another eicosanoid that exert

15 n by release of beta-hexosaminidase, PGD(2), leukotriene C(4) (LTC(4)), IL-5, IL-6, IL-13, GM-CSF, an

16 in, verapamil, CSA, and vanadate, but not by leukotriene C(4) (LTC(4)), indicating the involvement of

17 t proinflammatory lipid mediators comprising leukotriene C(4) (LTC(4)), LTD(4), and LTE(4).

18 a major source of the eicosanoids PGD(2) and leukotriene C(4) (LTC(4)), which contribute to allergic

19 achidonic acid (AA) release and secretion of leukotriene C(4) (LTC(4)).

20 levels of the cysteinyl leukotriene (cys-LT) leukotriene C(4) (LTC(4)).

21 Further, GGL-deficient mice show leukotriene C(4) accumulation and significantly more air

22 MRP1-dependent transport of leukotriene C(4) and estradiol-17beta-d-glucuronide into

23 nt transport of the glutathione S-conjugates leukotriene C(4) and S-(2, 4-dinitrophenyl)glutathione a

24 Our data show that the K(m) values for leukotriene C(4) are equivalent for GGT1 and GGT5 at 10.

25 ded in gel-phase EliCell preparations showed leukotriene C(4) generation at the nuclear envelope and

26 nulate and release eosinophil peroxidase and leukotriene C(4) in a dose-dependent manner.

27 D(4) in vivo either in blood when exogenous leukotriene C(4) is administered intravenously or in bro

28 F-alpha, IL-8, PGE(2), leukotriene B(4), and leukotriene C(4) levels were significantly reduced, as w

29 Treg or Tconv cells suppressed IgE-mediated leukotriene C(4) production but enhanced cytokine produc

30 However, arachidonic acid release and leukotriene C(4) production stimulated by zymosan and C.

31 PI3K-Akt cascades, as well as the increased leukotriene C(4) release observed in response to fMLP in

32 AT6(-/-) mice exhibited normal histamine and leukotriene C(4) release, but their cytokine release was

33 rs PD98059 or U0126 inhibited the release of leukotriene C(4) stimulated by fMet-Leu-Phe in IL-5-prim

34 rleukin (IL)-4 upregulates the expression of leukotriene C(4) synthase (LTC(4)S) by human cord blood-

35 Leukotriene C(4) synthase (LTC(4)S) is responsible for t

36 cally induced the steady-state expression of leukotriene C(4) synthase (LTC(4)S) mRNA within 6 h, and

37 sitized with D. farinae-pulsed BMDCs lacking leukotriene C(4) synthase (LTC(4)S), CysLT(1)R, or both

38 Leukotriene C(4) synthase (LTC(4)S), the terminal 5-lipo

39 ion and challenge protocol with mice lacking leukotriene C(4) synthase (LTC(4)S), the terminal enzyme

40 ely, in a strain with targeted disruption of leukotriene C(4) synthase to prevent cys-LT synthesis.

41 jury was observed in transgenic mice lacking leukotriene C(4) synthase, hemopoietic PGD(2) synthase,

42 , is primarily responsible for conversion of leukotriene C(4) to leukotriene D(4), the most potent of

43 al for the MRP1-mediated drug resistance and leukotriene C(4) transport activity.

44 sphingosine transporter Abcb1 (Mdr1) and the leukotriene C(4) transporter Abcc1 (Mrp1).

45 ands and CCR8 for emigration to DLN, but the leukotriene C(4) transporter multidrug resistance-relate

46 cretion and production of the lipid mediator leukotriene C(4) were unaffected.

47 nant mCysLT(2)R with a rank order of potency leukotriene C(4)(LTC(4) ) = LTD(4)>>LTE(4).

48 , transports conjugated organic anions (e.g. leukotriene C(4)) and also co-transports certain unmodif

49 re-induced leukotriene (leukotriene B(4) and leukotriene C(4)) production, indicating 5-lipoxygenase

50 (e.g., histamine), lipid metabolites (e.g., leukotriene C(4)), and cytokines (e.g., IL-4/IL-13), whi

51 d Synta-66 reduced the release of histamine, leukotriene C(4), and cytokines (IL-5/-8/-13 and TNFalph

52 Intranasal leukotriene C(4), D(4), and E(4) were administered to na

53 t cell (MC) mediators (histamine, serotonin, leukotriene C(4), prostaglandin D2, and mouse mast cell

54 as the release of the proinflammatory factor leukotriene C(4).

55 e substrate binding pockets of As(GS)(3) and leukotriene C(4).

56 release of eosinophil-derived neurotoxin and leukotriene C(4).

57 nist-induced prostaglandin E(2) (PGE(2)) and leukotriene C(4)/D(4)/E(4) production during lipoprotein

58 kines IL-4, IL-5, IL-13, IL-25, and eotaxin; leukotriene C(4); and total as well as allergen-specific